On 20 February 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Vokanamet for the treatment type 2 diabetes mellitus (EMA)
Diabetes News Service
On 20 February 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Vokanamet for the treatment type 2 diabetes mellitus (EMA)
For iPhone and iPad | For Android devices
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
Website by Wired up Wales